Clinical trials: CHF - Congestive Heart Failure
Ventricular Tachycardia, Ventricular Fibrillation
DAVID II (Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial II)
The DAVID II Clinical Study evaluates the hypothesis that, in patients needing an ICD but without overt indications for pacing, AAI pacing with maximal concomitant drug therapy will not increase the rate of the combined endpoint…
- Conditions
- Ventricular Tachycardia, Ventricular Fibrillation, Sudden Cardiac Death, Congestive Heart Failure
- Trial name
- DAVIDII (NCT00187187)
- Testing
- Implantable Defibrillator (ICD)
- Volunteers
- 600 people
- Sponsor
- Abbott Medical Devices
Congestive Heart Failure, Heart Failure
Heart Failure Event Advance Detection Trial
Patients who are admitted with acutely decompensated heart failure and are receiving intravenous diuretics will be recruited to undergo testing using the Indicor Device.
- Conditions
- Congestive Heart Failure, Heart Failure, Decompensated Heart Failure
- Trial name
- HEADstart (NCT04223271)
- Testing
- Indicor
- Where
- United States
- Volunteers
- 165 people
- Sponsor
- Vixiar Medical, Inc.
Heart Failure, Congestive
Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure
Different doses of relaxin will be compared to placebo to determine efficacy and safety for the treatment of patients hospitalized with acute heart failure
- Trial name
- RELAX-AHF (NCT00520806)
- Testing
- Relaxin
- Where
- 3 sites in United States, Israel
- Volunteers
- 1,161 people
- Sponsor
- Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies
Heart Failure (HF)
A Trial to Study BAY1753011 in Patients With Congestive Heart Failure
To assess the efficacy of 30 mg of BAY1753011, with or without furosemide, versus furosemide alone in patients with heart failure and objective evidence of congestion.
- Trial name
- AVANTI (NCT03901729)
- Testing
- BAY 1753011, Furosemide
- Where
- 66 sites in Austria, Bulgaria and 7 more
- Volunteers
- 482 people
- Sponsor
- Bayer
Congestive Heart Failure
Safety and Efficacy of Furosemide 40mg + Amiloride Hydrochloride 10mg to Reduct Edema
The study consists in two treatment groups, one group will receive Diurisa® (furosemide 40 mg + amiloride chloride 10 mg) and the other one will receive furosemide 40 mg (Lasix®)
- Trial name
- NCT01210365
- Testing
- Diurisa®, Lasix ®
- Where
- 4 sites in Brazil
- Volunteers
- 27 people
- Sponsor
- Eurofarma Laboratorios S.A.
Congestive Heart Failure
The V-Wave Shunt: FIM Safety and Feasibility Study
The V-Wave atrial-septal shunt implant is intended for the reduction of elevated left atrial filling pressures ('Left Atrial Decompression') in chronic, New York Heart Association (NYHA) class III -IV, Heart Failure (HF)…
- Trial name
- VW-SP-1 (NCT01965015)
- Testing
- Implantation of the V-Wave inter-atrial shunt
- Where
- 6 sites in Germany, Israel and 1 more
- Volunteers
- 16 people
- Sponsor
- V-Wave Ltd
Congestive Heart Failure
Relation of Non-invasively Measured Parameters to Clinical Outcomes in CHF Patients
Our aim is to assess whether changes in CO, CI and SVR as measured using the Biobeat wearable, wireless, non-invasive device during IV diuretic administration in an outpatient setting among CHF patients correlate with short-term…
- Trial name
- NCT04548024
- Testing
- Short term monitoring
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Biobeat Technologies Ltd.
Acute Decompensated Heart Failure, Sleep Disordered Breathing
Cardiovascular Improvements With MV ASV Therapy in Heart Failure
The aim of the study is to compare the effects of MV targeted ASV in addition to optimized medical therapy versus optimized medical therapy alone at 6 months in patients with acute decompensated HF.
- Trial name
- CAT-HF (NCT01953874)
- Testing
- MV ASV, Optimized Medical Treatment
- Where
- 15 sites in United States, Germany
- Volunteers
- 126 people
- Sponsor
- ResMed
Acute Decompensated Heart Failure
IC14 for Treatment of Acute Decompensated Heart Failure
The goal of this clinical trial is to learn if drug atibuclimab (IC14) works to treat adults hospitalized with acute decompensated heart failure (ADHF). It will also learn about the safety of IC14.
- Trial name
- NCT06556810
- Testing
- Atibuclimab (IC14)
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Implicit Bioscience
Essential (Primary) Hypertension, Hypertensive Heart Disease With (Congestive) Heart Failure
Positive Care Effect of the Digital Health Assistant ADELE Blood Pressure for Hypertension Patients
High blood pressure (hypertension) can cause damage to vital organs such as the heart, kidneys, eyes, brain and blood vessels. The risk of developing high blood pressure increases with age.
- Conditions
- Essential (Primary) Hypertension, Hypertensive Heart Disease With (Congestive) Heart Failure, Hypertensive Heart Disease Without (Congestive) Heart Failure, Other Secondary Hypertension
- Trial name
- A0007 (NCT06663280)
- Testing
- Digital health assistant ADELE
- Where
- 2 sites in Germany
- Volunteers
- 108 people
- Sponsor
- Alma Phil Gmbh
Heart Failure, Congestive
A Study of the Safety and Efficacy of Follow-up Serial Infusions of Natrecor(Nesiritide) for the Management of Patients With Heart Failure
The purpose of this study is to evaluate the efficacy and safety of Nesiritide administered as serial infusions to heart failure (HF) patients in the outpatient setting.
- Trial name
- NCT00091520
- Testing
- Nesiritide
- Volunteers
- 920 people
- Sponsor
- Scios, Inc.
Congestive Heart Failure
Study to Compare the Effects of Two Dosages of Tolvaptan in Congestive Heart Failure Patients
Patients with congestive heart failure will be assessed for safety and clinical effects of Tolvaptan 30 mg every day versus 15 mg twice a day over a period of 7 days.
- Trial name
- NCT00043771
- Testing
- Tolvaptan
- Where
- 9 sites in United States
- Volunteers
- 40 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Any Patient Who Fulfills the Inclusion Criteria to be Implanted With a Dual Chamber Pacemaker Maybe Included in the Study as Per ACC/AHA Guidelines
Comparison of AAIsafeR and DDD Modes in Non-selected Patients
1 Purpose In patients with sinus node dysfunction (SND), the use of AAI mode is rare. In paroxysmal high-degree or complete atrio-ventricular (AV) block, paroxysmal vagally-mediated bradycardia, single chamber atrial pacemakers…
- Trial name
- CAN-SAVE R (NCT01219621)
- Testing
- Symphony Dual Chamber Rate Responsive Device
- Where
- 10 sites in Canada
- Volunteers
- 450 people
- Sponsor
- Sorin Group Canada
Tachycardia, Congestive Heart Failure
MADIT-CRT: Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy
The MADIT-CRT trial is designed to determine if combined implantable cardiac defibrillator (ICD)-cardiac resynchronization therapy (CRT-D) will reduce the risk of mortality and heart failure (HF) events by approximately 25%, in…
- Trial name
- MADIT-CRT (NCT00180271)
- Testing
- Cardiac resynchronization therapy with defibrillation, Implantable Cardioverter Defibrillator (ICD)
- Where
- United States
- Volunteers
- 1,820 people
- Sponsor
- Boston Scientific Corporation
Coronary Artery Bypass Surgery, Coronary Heart Disease
Clinical Study to Evaluate Nesiritide in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery A014 / NAPA
The purpose of this study is to assess the effects of nesiritide compared to placebo when given with standard of care therapies, on kidney function, heart function and the need of other treatments in heart failure patients…
- Conditions
- Coronary Artery Bypass Surgery, Coronary Heart Disease, Coronary Artery Bypass Grafting, Cardiopulmonary Bypass
- Trial name
- NCT00653042
- Testing
- Nesiritide
- Volunteers
- 305 people
- Sponsor
- Scios, Inc.
CHF, Congestive Heart Failure
Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF
Sensorum Health (Sensorum) is conducting a pilot study to determine if Sensorum's proprietary passive sensor network can be used to identify signals of early health decompensation in subjects prior to a hospitalization for…
- Trial name
- NCT05865197
- Testing
- Data collection
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Sensorum Health Inc.
Heart Failure (HF)
A Study of Ivabradine in African-American/ Black Subjects With Heart Failure and Left Ventricular Systolic Dysfunction.
This study is a prospective, open-label, single-arm intervention study in African-American/Black subjects with heart failure and reduced ejection fraction (HFrEF).
- Trial name
- NCT03456856
- Testing
- Ivabradine
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Amgen
Heart Failure
A Phase II Dose-escalation Study to Assess the Feasibility and Safety of Transendocardial Delivery of Three Different Doses of Allogeneic Mesenchymal Precursor Cells (MPCs)in Subjects With Heart Failure
This is a dose-ranging clinical study to evaluate the feasibility, safety, and tolerability of 3 different doses of immunoselected, culture expanded, nucleated, allogeneic MPCs in subjects who have cardiomyopathy of both ischemic…
- Trial name
- NCT00721045
- Testing
- Mesenchymal Precursor Cells (MPCs), standard-of-care treatment with mock mapping and injection procedures.
- Where
- 6 sites in United States
- Volunteers
- 60 people
- Sponsor
- Mesoblast, Ltd.
Venous Thromboembolism
Dalteparin vs Unfractionated Heparin For The Prevention Of Venous Thromboembolism (VTE) In Hospitalized Acutely Ill Medical Patients
The purpose of this study is to compare the efficacy and safety of dalteparin vs unfractionated heparin for the prevention of VTE (Venous Thromboembolism) in hospitalized acutely ill medical patients.
- Trial name
- NCT00445328
- Testing
- Dalteparin (Fragmin), Unfractionated heparin
- Where
- 7 sites in India
- Volunteers
- 84 people
- Sponsor
- Pfizer
Heart Failure, Congestive
Study of DITPA in Patients With Congestive Heart Failure
This study will assess the safety and efficacy of DITPA relative to placebo in patients with New York Heart Association (NYHA) class III or IV congestive heart failure (CHF) who have low serum T3.
- Trial name
- NCT00103519
- Testing
- DITPA (3,5-diiodothyropropionic acid)
- Where
- 22 sites in United States
- Volunteers
- 86 people
- Sponsor
- Titan Pharmaceuticals